Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorogenic acid for injection in advanced lung cancer
NCT03751592Phase 2Unknown
- Sponsor
- Sichuan Jiuzhang Biotechnology
- Start
- Jul 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chlorogenic acid in Lung Cancer (LC), small cell lung cancer (SCLC), squamous cell carcinoma of the lung (SCCL) and 1 more, sponsored by Sichuan Jiuzhang Biotechnology. Primary endpoint: Disease Control Rate at 10 weeks. Status: unknown.
02
Drugs
chlorogenic acid
03
Conditions
Lung Cancer (LC)small cell lung cancer (SCLC)squamous cell carcinoma of the lung (SCCL)lung adenocarcinoma
Beyond the preview
Go deeper on NCT03751592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751592.